Sustainability

Implementing the concept of environmental protection and fulfilling the corporate social responsibility, committed to becoming the world’s leading sustainable pharmaceutical enterprise

Continuously Enhancing Sustainability Practices
MSCI ESG Rating: AAA
S&P Global ESG Score: 67, Surpassing 92% of Global Peers

Environmental, Social and Governance Report

Full Report

Environmental, Social and Governance Committee

Terms of Reference

Sustainability News

Undertaking corporate social responsibility to build healthy, harmonious and sustainable communities

CMS Charity | Love Like Starlight: CMS Continues to Care for Children’s Growth

Growing toward the light, together in warmth. With International Children’s Day approaching, China Medical System Holdings Limited (“CMS”), through its subsidiary Shenzhen Kangzhe, continued its long-standing philanthropic initiatives. Via the Charity Association of Shenzhen Nanshan, CMS donated funds to the Star Exceptional Children Rehabilitation Center in Nanshan District, Shenzhen. The donation will be used to upgrade teaching aids, add rehabilitation equipment, and provide support for frontline teachers—helping improve learning, rehabilitation, and living conditions for exceptional children. Over the years, CMS has stood side-by-side with the Center, witnessing every small step of progress in the rehabilitation and growth of these children. This enduring commitment stems from a deep compassion for special-needs children and a profound understanding of philanthropic values: their development demands patience, sustained support, and collective care from society. In addition, CMS donated 10 computers to the Green & Shine Foundation to help improve educational facilities in schools across central and western China, supporting daily teaching […]

CMS Included in S&P Global Sustainability Yearbook (China Edition) for the Fourth Consecutive Year

S&P Global, an internationally recognized rating agency, recently released the Sustainability Yearbook (China Edition) 2026. China Medical System (“CMS” or the “Group”) stood out among nearly 1,800 companies and was successfully included for the fourth consecutive year, underscoring the Group’s long-term resilience and comprehensive strengths in sustainable development. （Source：S&P Global） CMS integrates the United Nations Sustainable Development Goals (“SDGs”) into the Group’s ESG strategy, guided by top-level planning, is driving a more sustainable transformation across the entire value chain. We are committed to improving accessibility and equity in healthcare, and continue to increase R&D investment in innovative medicines and treatments for rare diseases, addressing unmet clinical needs through scientific innovation. At the same time, we remain dedicated to inclusive healthcare, responding to societal needs through concrete actions and fulfilling the responsibilities expected of a pharmaceutical company. We also place strong emphasis on employee development and environmental protection, and steadily advance our responsible practices. The Group’s […]

CMS Recognized in S&P Global Sustainability Yearbook for Second Consecutive Year

Recently, S&P Global, an internationally authoritative rating agency, has released the Sustainability Yearbook 2026 (the “Yearbook”). China Medical System (“CMS” or the “Group”) has stood out among 9,200 participating companies and successfully secured a place in the Yearbook, with a 2025 Corporate Sustainability Assessment (CSA) score of 66, surpassing 92% of global peers. This marks the second consecutive year that CMS has earned this international honor. Source: S&P Global Guided by its long-term ESG strategic objectives, CMS has deeply integrated the concept of sustainable development into its strategic decision-making and daily operations. The Group is driven by the dual engines of in-house R&D and collaborative R&D, continuously enhancing the accessibility and affordability of healthcare services and working to narrow health disparities across different regions and populations. Concurrently, we actively fulfill our corporate social responsibilities, leveraging innovative biotechnology to drive industry advancement and contribute to the sustained improvement of social well-being. Our sustainability performance has also been recognized by multiple authoritative rating agencies: MSCI ESG Rating maintained at “AA”; the Hong Kong […]